Protalix BioTherapeutics, Inc.
PLX · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $176,005 | $116,423 | $196,127 | $138,274 |
| - Cash | $13,647 | $17,895 | $19,458 | $19,760 |
| + Debt | $8,177 | $5,349 | $5,236 | $5,526 |
| Enterprise Value | $170,535 | $103,877 | $181,905 | $124,040 |
| Revenue | $17,851 | $15,658 | $10,113 | $18,218 |
| % Growth | 14% | 54.8% | -44.5% | – |
| Gross Profit | $9,527 | $9,788 | $1,933 | $14,332 |
| % Margin | 53.4% | 62.5% | 19.1% | 78.7% |
| EBITDA | $2,791 | $1,804 | -$3,380 | $7,656 |
| % Margin | 15.6% | 11.5% | -33.4% | 42% |
| Net Income | $2,355 | $164 | -$3,619 | $6,494 |
| % Margin | 13.2% | 1% | -35.8% | 35.6% |
| EPS Diluted | 0.03 | 0.002 | -0.047 | 0.086 |
| % Growth | 1,400% | 104.2% | -155.1% | – |
| Operating Cash Flow | -$3,732 | -$5,233 | -$5,058 | $3,991 |
| Capital Expenditures | -$498 | -$431 | -$306 | -$425 |
| Free Cash Flow | -$4,230 | -$5,664 | -$5,364 | $3,566 |